Sign in
Taking people in SwedenPhase 1

Safety of the medicine CV-01 in healthy adults and adults with drug resistant epilepsy

Tests the safety of CV-01 in healthy adults and adults with drug resistant epilepsy.

Key facts

Who runs it
Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Enunciabile Anche Angelini Pharma Italia S.p.A. Angelini Pharma S.p.A. A.C.R.A.F. S.p.A. Acraf S.p.A. Angelini S.p.A. aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
Where
Moelndal and Uppsala, SwedenSee the 2 sites
Registry title
A randomized, multiple ascending doses, clinical trial to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of CV-01 after double-blind, placebo-controlled multiple oral administrations for 2 weeks in healthy volunteers, and multiple oral administrations open-label for 2 weeks in a cohort of participants with drug resistant epilepsy
Status
Recruiting
Phase
Phase 1
People taking part
36 people, planned
Started
17 Aug 2026
Expected to end
30 Aug 2027
Type of study
Interventional
Record updated
8 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for healthy volunteers and for adults with drug resistant epilepsy to test the safety and effects of CV-01 taken by mouth for 2 weeks.

Age
18 years or older
Sex
Men and women can join.
Disease stage
Drug resistant epilepsy (one group of the trial). Healthy volunteers can also join.

Where in Sweden

  • CTC Clinical Trial Consultants ABMoelndal, SwedenTaking people
  • CTC Clinical Trial Consultants ABUppsala, SwedenTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Plain-language title
Safety of the medicine CV-01 in healthy adults and adults with drug resistant epilepsyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
8 June 2026